Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.60 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140239 | 0.91 | PIK3CA (0.55) | ABCG2ABCB1ABCC1PIK3CAPIK3CB | |
| SCHEMBL4138246 | 0.89 | PIK3CA (0.67) | ABCG2ABCB1ABCC1PIK3CAPIK3CB | |
| SCHEMBL4138240 | 0.88 | PIK3CA (0.58) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL4133829 | 0.88 | PIK3CA (0.58) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL4140294 | 0.85 | PIK3CA (0.70) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL4145858 | 0.83 | PIK3CA (0.55) | ABCG2ABCB1ABCC1PIK3CAPIK3CB | |
| SCHEMBL4143852 | 0.83 | PIK3CA (0.57) | ABCG2PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL4128479 | 0.83 | PIK3CA (0.57) | ABCG2ABCC1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL4622260 | 0.81 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL4138231 | 0.80 | PIK3CA (0.58) | ABCG2ABCB1ABCC1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | claimed |
| EP-1945627-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2008-07-23 | — | — | EP | claimed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | claimed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | NR3C1, NR4A3, NR4A1 | ABCG2 1903/4885ABCB1 1821/4885ABCC1 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.